Stay updated with breaking news from Pascal Touchon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) has earned a consensus recommendation of “Hold” from the nine analysts that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and three have issued a buy recommendation on the company. The […]
Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) saw a large growth in short interest in March. As of March 15th, there was short interest totalling 16,700,000 shares, a growth of 18.7% from the February 28th total of 14,070,000 shares. Based on an average daily volume of 1,270,000 shares, the short-interest ratio is currently 13.1 days. […]
Analysts at StockNews.com started coverage on shares of Atara Biotherapeutics (NASDAQ:ATRA – Get Rating) in a report released on Thursday. The firm set a “hold” rating on the biotechnology company’s stock. ATRA has been the subject of several other reports. Mizuho reissued a “buy” rating and set a $31.00 price target on shares of Atara […]
These companies are among the best and brightest in the immunotherapy field.
Lazard Asset Management LLC purchased a new position in shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 11,922 shares of the biotechnology company’s stock, valued at approximately $45,000. Several other institutional investors and hedge funds […]